Sign In
Buy KALA
$3.54
-0.0700 (-1.94%)
At Close: Jun 22, 2026
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Tuesday, 05'th Sep 2023
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
08:00am, Friday, 04'th Aug 2023
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarde
KALA BIO to Participate in Upcoming Investor Conferences in August
04:01pm, Wednesday, 02'nd Aug 2023
ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 19'th Jul 2023
ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement aw
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
08:00am, Friday, 02'nd Jun 2023
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
08:00am, Tuesday, 09'th May 2023
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 --
MENLO PARK, Calif. and ARLINGTON, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development
KALA Up on Fast Track Designation to Lead Ocular Candidate
12:56pm, Thursday, 13'th Apr 2023
KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.
--No safety issues identified in Cohort 1 -- -- Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled t
Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know
11:27am, Friday, 24'th Mar 2023
The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana
4 Biotech Stocks to Consider for Your Portfolio in 2023
01:00pm, Tuesday, 21'st Mar 2023
New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KAL
Wall Street Bulls Look Optimistic About Kala Pharma (KALA): Should You Buy?
10:45am, Monday, 20'th Mar 2023
The average brokerage recommendation (ABR) for Kala Pharma (KALA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-aft
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
04:01pm, Wednesday, 08'th Mar 2023
ARLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization o
KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus
02:18pm, Monday, 06'th Mar 2023
Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6.
Kala Pharmaceuticals (KALA) Flat As Market Sinks: What You Should Know
07:34pm, Wednesday, 22'nd Feb 2023
Kala Pharmaceuticals (KALA) closed the most recent trading day at $11.90, making no change from the previous trading session.
